Heska Corp. (HSKA:NASDAQ) sells advanced veterinary diagnostic and other specialty veterinary products. The company’s core focus is on the canine and feline markets where the company strives to provide high-value products and customer support to veterinarians.

Heska’s business is comprised of two segments – core companion animal health along with other vaccines, pharmaceuticals and products. The range of products that Heska offers to its customers includes diagnostic instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals.

On August 11, 2008, Heska reported financial results for its second quarter ended June 30, 2008. The company generated its highest second quarter revenue figure ever. For the three months ended June 30, 2008, Heska had total revenues of $22.6 million, an increase of 13% from the prior year period. The company also posted record second quarter income from operations of $1.4 million for the three months ended June 30, 2008.

When broken down by segments, revenues for the core companion animal health segment grew by 7% to $17.3 million. Revenues for the other vaccines, pharmaceuticals, and other products segment grew by 38% to $4.9 million. Revenue from Heska’s new chemistry instrument – the Heska Dr-Chem 4000 Veterinary Clinical Chemistry Analyzer by FUJIFILM – was a major factor in the growth of revenues for the company’s key core companion animal health segment.

Let us hear your thoughts below:

Last 5 posts by QualityStocks

• Omnicity Corp. (OMCY.OB) Announces Addition of New Board Member - November 20th, 2009
• Muscle Flex, Inc. (MFLI.PK) Announces Release Time for the BUDDY Tablet Caddy Two-Minute Commercial and Landing Page - November 20th, 2009
• Artfest International, Inc. (ARTS.OB) Announces Revenue Profit Jumps - November 20th, 2009
• Omnicity Corp.’s (OMCY.OB) Recently-Issued Corporate Update - November 20th, 2009
• Soligenix Inc. (SNGX.OB) Taking Steps to Meet Challenges of Vaccine Technology and Biological Warfare - November 20th, 2009